BTK and B-cell chronic lymphocytic leukemia: Based on our previous observation that the active phosphorylated form of BTK (Y223), but not total BTK, was significantly higher in CLL B-cells than in normal B cells [9], we conjectured that greater BTK activity may underlie the better clinical responses of UM-CLL subgroup to ibrutinib.